NO980299L - Cytokinproduksjonsinhibitorer, preparater derav og deres anvendelse i medisin, samt fremgangsmåter for deres identifikasjon - Google Patents
Cytokinproduksjonsinhibitorer, preparater derav og deres anvendelse i medisin, samt fremgangsmåter for deres identifikasjonInfo
- Publication number
- NO980299L NO980299L NO980299A NO980299A NO980299L NO 980299 L NO980299 L NO 980299L NO 980299 A NO980299 A NO 980299A NO 980299 A NO980299 A NO 980299A NO 980299 L NO980299 L NO 980299L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- preparations
- medicine
- identification
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000016396 cytokine production Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010054805 Macroangiopathy Diseases 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9611046.5A GB9611046D0 (en) | 1996-05-25 | 1996-05-25 | Pharmacological compounds |
| PCT/GB1997/001415 WO1997045417A1 (en) | 1996-05-25 | 1997-05-23 | Cytokine production inhibitors, formulations thereof and their use in medicine, and methods for their identification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO980299D0 NO980299D0 (no) | 1998-01-23 |
| NO980299L true NO980299L (no) | 1998-03-24 |
Family
ID=10794362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO980299A NO980299L (no) | 1996-05-25 | 1998-01-23 | Cytokinproduksjonsinhibitorer, preparater derav og deres anvendelse i medisin, samt fremgangsmåter for deres identifikasjon |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0859762A1 (pt) |
| JP (1) | JPH11510521A (pt) |
| AU (1) | AU2910397A (pt) |
| BR (1) | BR9702238A (pt) |
| CA (1) | CA2227811A1 (pt) |
| GB (1) | GB9611046D0 (pt) |
| HU (1) | HUP9902796A3 (pt) |
| IL (1) | IL123033A0 (pt) |
| NO (1) | NO980299L (pt) |
| WO (1) | WO1997045417A1 (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CN1997646A (zh) | 2004-06-16 | 2007-07-11 | 惠氏公司 | 作为β－分泌酶抑制剂的二苯基咪唑并嘧啶胺和二苯基咪唑并咪唑胺 |
| CN1968945A (zh) | 2004-06-16 | 2007-05-23 | 惠氏公司 | 用于抑制β分泌酶的氨基－5,5－二苯基咪唑酮衍生物 |
| CN101103034A (zh) | 2005-01-14 | 2008-01-09 | 惠氏公司 | 抑制β-分泌酶的氨基-咪唑酮 |
| KR20070107062A (ko) | 2005-02-01 | 2007-11-06 | 와이어쓰 | β-세크리타제의 억제제로서의 아미노-피리딘 |
| JP2008530103A (ja) | 2005-02-14 | 2008-08-07 | ワイス | β−セクレターゼ阻害剤としてのアゾリルアシルグアニジン |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| KR20080050430A (ko) | 2005-09-26 | 2008-06-05 | 와이어쓰 | 베타-세크레타제 (ｂａｃｅ) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물 |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| US7700606B2 (en) | 2006-08-17 | 2010-04-20 | Wyeth Llc | Imidazole amines as inhibitors of β-secretase |
| JP2010512389A (ja) | 2006-12-12 | 2010-04-22 | シェーリング コーポレイション | アスパルチルプロテアーゼ阻害剤 |
| CL2008000791A1 (es) | 2007-03-23 | 2008-05-30 | Wyeth Corp | Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4005205A (en) * | 1974-04-24 | 1977-01-25 | Smith Kline & French Laboratories Limited | Compositions and methods for inhibiting H2 histamine receptors |
| GR79384B (pt) * | 1982-08-20 | 1984-10-22 | Hoechst Uk Ltd | |
| PT77842B (en) * | 1982-12-21 | 1986-05-05 | Pfizer | Process for preparing dihydropyridines |
| GB8311443D0 (en) * | 1983-04-27 | 1983-06-02 | Smith Kline French Lab | Chemical compounds |
| CA1252788A (en) * | 1985-03-12 | 1989-04-18 | William J. Coates | Pyridazinone derivatives |
| FI902321A7 (fi) * | 1989-05-19 | 1990-11-20 | Eisai Co Ltd | Buteenihappojohdannaiset |
| GB9506188D0 (en) * | 1995-03-27 | 1995-05-17 | Fujisawa Pharmaceutical Co | Amidine derivatives |
-
1996
- 1996-05-25 GB GBGB9611046.5A patent/GB9611046D0/en active Pending
-
1997
- 1997-05-23 WO PCT/GB1997/001415 patent/WO1997045417A1/en not_active Ceased
- 1997-05-23 EP EP97923245A patent/EP0859762A1/en not_active Withdrawn
- 1997-05-23 IL IL12303397A patent/IL123033A0/xx unknown
- 1997-05-23 HU HU9902796A patent/HUP9902796A3/hu unknown
- 1997-05-23 CA CA002227811A patent/CA2227811A1/en not_active Abandoned
- 1997-05-23 BR BR9702238A patent/BR9702238A/pt not_active Application Discontinuation
- 1997-05-23 AU AU29103/97A patent/AU2910397A/en not_active Abandoned
- 1997-05-23 JP JP9541830A patent/JPH11510521A/ja active Pending
-
1998
- 1998-01-23 NO NO980299A patent/NO980299L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9702238A (pt) | 1999-07-27 |
| JPH11510521A (ja) | 1999-09-14 |
| HUP9902796A2 (hu) | 2000-04-28 |
| WO1997045417A1 (en) | 1997-12-04 |
| NO980299D0 (no) | 1998-01-23 |
| EP0859762A1 (en) | 1998-08-26 |
| CA2227811A1 (en) | 1997-12-04 |
| GB9611046D0 (en) | 1996-07-31 |
| HUP9902796A3 (en) | 2000-07-28 |
| IL123033A0 (en) | 1998-09-24 |
| MX9800670A (es) | 1998-09-30 |
| AU2910397A (en) | 1998-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO980299L (no) | Cytokinproduksjonsinhibitorer, preparater derav og deres anvendelse i medisin, samt fremgangsmåter for deres identifikasjon | |
| CA2597273C (en) | Proteasome inhibitors and methods of using the same | |
| ATE193827T1 (de) | Verwendung von 1-2-4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren | |
| ATE244220T1 (de) | Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung | |
| DE3687501D1 (de) | Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus. | |
| NO973635L (no) | Fremgangsmåte for hemming av celle-celle adhesjon | |
| MY119350A (en) | Propiophenone derivatives and process for preparing the same | |
| NZ530782A (en) | Aminoisoxazole derivatives active as kinase inhibitors | |
| ATE295346T1 (de) | N-(aryl/heteroarylacetyl)aminosäureester, diese enthaltende pharmazeutische zusammensetzungen und methoden zur inhibierung der beta- amyloidfreisetzung und/oder deren synthese unter verwendung dieser verbindungen | |
| ATE60579T1 (de) | Pyrrolidinamid-derivate mit antipropylendopeptidase-wirkung, zusammenstellungen, die sie enthalten, verfahren zu ihrer herstellung und heilmittel, die sie enthalten. | |
| DK11391A (da) | Alkoxy-4(1h)-pyridonderivater og farmakologisk acceptable salte deraf, deres fremstilling og anvendelse | |
| ATE189601T1 (de) | Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen | |
| DE69332353D1 (de) | Verwendung von inhibitoren der synthese von fettsäuren zur behandlung von krebs | |
| DE4111394A1 (de) | Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel | |
| NO955326L (no) | Isokinolinderivater, fremgangsmåte for deres fremstilling og terapeutiske anvendelse | |
| NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
| JPH0363294A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| DK549388D0 (da) | 17-androstancarboxylsyreestere, fremgangsmaade til fremstilling heraf og farmaceutisk praeparat indeholdende samme | |
| ATE18549T1 (de) | 1-carboxyalkanoylindolin-2-carbonsaeure-ester, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung. | |
| DE69432124D1 (de) | Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes | |
| EP0532553B1 (en) | Use of compounds for the treatment of age-related memory impairment and other cognitive disorders | |
| WO1997014966B1 (en) | Method of activating a novel ligand regulatory pathway | |
| NO950665L (no) | Nye polyjoderte forbindelser, fremgangsmåte for deres fremstilling og kontrastmidler inneholdende disse | |
| DE69818051D1 (de) | N-benzenesulfonyl-l-prolin-derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
| Lum et al. | Thrombin receptor activation peptide induces pulmonary vasoconstriction |